Edwards Lifesciences (EW) announced that Scott Ullem, the company’s chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences reports Q3 adjusted EPS 67c, consensus 59c
- Edwards Lifesciences raises FY25 EPS view to $2.56-$2.62, consensus $2.51
- Notable companies reporting after market close
- Skyworks upgraded, UnitedHealth downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Buy from Hold at Jefferies